Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.41. Xtant Medical shares last traded at $0.37, with a volume of 541,085 shares.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum set a $1.50 target price on shares of Xtant Medical and gave the stock a "buy" rating in a report on Friday, October 18th.
View Our Latest Analysis on XTNT
Xtant Medical Stock Performance
The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last released its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%. The firm had revenue of $27.94 million during the quarter.
Institutional Investors Weigh In On Xtant Medical
Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of Xtant Medical by 70.2% during the 3rd quarter. Geode Capital Management LLC now owns 515,006 shares of the medical device company's stock worth $348,000 after acquiring an additional 212,394 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Xtant Medical by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company's stock valued at $1,812,000 after buying an additional 48,319 shares in the last quarter. Finally, Evernest Financial Advisors LLC purchased a new position in shares of Xtant Medical during the 3rd quarter valued at approximately $27,000. Hedge funds and other institutional investors own 69.33% of the company's stock.
Xtant Medical Company Profile
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
See Also
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
